Resistance to cancer therapies like cirzotinib against fusion oncogenic proteins, such as EML4-ALK in non-small cell lung cancer (NSCLC), can be explained by a localizer c-mod mechanism of action (Gonzalez-Martinez et al., 2022). Here, ALK is linked to cancer.